Levodopa-Karbidopa Bağırsak Jeli Parkinson Hastalığında Dyskineziyi Geliştirir: COSMOS Çalışmasından Post Hoc Analizi.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundDyskinesia is a debilitating complication of dopaminergic therapy in advanced Parkinson's disease.ObjectivesTo evaluate the effect of levodopa-carbidopa intestinal gel (LCIG) on dyskinesia burden.MethodsThis is a post hoc analysis of the retrospective, observational COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS; NCT03362879). Change in dyskinesia was assessed by LCIG treatment group (monotherapy, daytime monotherapy, polytherapy), baseline dyskinesia duration (ResultsOver 50% (202/369) of LCIG-treated patients experienced improvement in dyskinesia severity. Improvements in dyskinesia duration and severity were noted in all treatment groups. The proportion of patients with troublesome dyskinesia and amount of "Off" time significantly decreased from baseline to study visit, regardless of baseline dyskinesia burden (P ConclusionLCIG led to reductions in dyskinesia severity, regardless of baseline dyskinesia burden. Dyskinesia duration improved in patients with high dyskinesia burden but not in those with low dyskinesia burden.

İlgili konular